The Environmental Protection Agency (EPA) proposed adding microplastics and pharmaceuticals to its Contaminant Candidate List (CCL) for drinking water, marking the first time these substances have been formally recognized as potential threats. The draft list, part of the Safe Drinking Water Act, opens a 60-day public comment period before finalization by mid-November.
Immediate Action & Core Facts
EPA Administrator Lee Zeldin and Health Secretary Robert F. Kennedy Jr. announced the move, citing public concern over microplastics and pharmaceuticals in drinking water. The inclusion does not impose regulations but could lead to future limits. Studies have detected microplastics in human organs and pharmaceuticals in water supplies, though health impacts remain under study.
Deeper Dive & Context
Policy Implications
The CCL identifies contaminants for research and potential regulation. The EPA rarely moves pollutants from the list to enforce limits, as seen with its March decision not to regulate nine previously listed pollutants. Critics argue the move is symbolic, while supporters see it as a necessary first step.
Scientific and Public Health Perspectives
Researchers like Sherri Mason of Gannon University highlight the importance of recognizing microplastics as contaminants. Others, such as Erik Olson of the Natural Resources Defense Council, note the process often ends without action. Pharmaceuticals, particularly antidepressants, enter water through human excretion and inadequate wastewater treatment.
Political and Advocacy Views
The MAHA (Make America Healthy Again) movement, led by Kennedy, has pressured the EPA to address environmental contaminants. Some advocates, like Earthjustice’s Katherine O’Brien, call the move “theater,” citing simultaneous rollbacks of chemical regulations. The EPA’s decision follows criticism of Zeldin’s plans to loosen restrictions on harmful chemicals.
Public and Industry Reactions
The proposal responds to widespread public concern over water safety. Water utilities may face future regulatory burdens if limits are set. The EPA’s $144 million STOMP program aims to study microplastics’ presence and health effects.